Lavipharm S.A.

ATSE:LAVI Stock Report

Market Cap: €235.8m

Lavipharm Dividends and Buybacks

Dividend criteria checks 0/6

Lavipharm is a dividend paying company with a current yield of 1.43%.

Key information

1.4%

Dividend yield

0.08%

Buyback Yield

Total Shareholder Yield1.5%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ratio172%

Recent dividend and buyback updates

Recent updates

Even With A 27% Surge, Cautious Investors Are Not Rewarding Lavipharm S.A.'s (ATH:LAVI) Performance Completely

Jan 28
Even With A 27% Surge, Cautious Investors Are Not Rewarding Lavipharm S.A.'s (ATH:LAVI) Performance Completely

Lavipharm (ATH:LAVI) Takes On Some Risk With Its Use Of Debt

Dec 18
Lavipharm (ATH:LAVI) Takes On Some Risk With Its Use Of Debt

We Think Shareholders Should Be Aware Of Some Factors Beyond Lavipharm's (ATH:LAVI) Profit

Apr 10
We Think Shareholders Should Be Aware Of Some Factors Beyond Lavipharm's (ATH:LAVI) Profit

Lavipharm's (ATH:LAVI) Earnings Aren't As Good As They Appear

Sep 26
Lavipharm's (ATH:LAVI) Earnings Aren't As Good As They Appear

Some Shareholders Feeling Restless Over Lavipharm S.A.'s (ATH:LAVI) P/E Ratio

Aug 06
Some Shareholders Feeling Restless Over Lavipharm S.A.'s (ATH:LAVI) P/E Ratio

Here's Why Lavipharm (ATH:LAVI) Has A Meaningful Debt Burden

Nov 01
Here's Why Lavipharm (ATH:LAVI) Has A Meaningful Debt Burden

We're Not Counting On Lavipharm (ATH:LAVI) To Sustain Its Statutory Profitability

Feb 11
We're Not Counting On Lavipharm (ATH:LAVI) To Sustain Its Statutory Profitability

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Too early to tell whether LAVI's dividend payments have been stable as they only just started paying a dividend.

Growing Dividend: Too early to tell if LAVI's dividend payments are increasing as they only just started paying a dividend.


Dividend Yield vs Market

Lavipharm Dividend Yield vs Market
How does LAVI dividend yield compare to the market?
SegmentDividend Yield
Company (LAVI)1.4%
Market Bottom 25% (GR)2.1%
Market Top 25% (GR)5.2%
Industry Average (Pharmaceuticals)2.7%
Analyst forecast (LAVI) (up to 3 years)n/a

Notable Dividend: LAVI's dividend (1.43%) isn’t notable compared to the bottom 25% of dividend payers in the Greek market (2.08%).

High Dividend: LAVI's dividend (1.43%) is low compared to the top 25% of dividend payers in the Greek market (5.22%).


Earnings Payout to Shareholders

Earnings Coverage: With its high payout ratio (172.4%), LAVI's dividend payments are not well covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Insufficient data to calculate LAVI's cash payout ratio to determine if its dividend payments are covered by cash flows.


Discover strong dividend paying companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/24 19:31
End of Day Share Price 2026/04/24 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Lavipharm S.A. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.